All News
Industry Press Releases - BMS, Abbvie, UCB, Janssen
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting.
Read Article
Excellent scientific session on #SpA at #ACR21 right now- especially like this clear diagram of pathophysiology and useful summary slide from Dr Nigil Haroon on differences between #axSpA and axial #PsA
@RheumNow https://t.co/F7Ns7e9HQI
Mrinalini Dey DrMiniDey ( View Tweet)
“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21
Dr. Antoni Chan synovialjoints ( View Tweet)
Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN
Richard Conway RichardPAConway ( View Tweet)
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 #ACRBest @Rheumnow
Abst #0452 Raychaudhuri et al.
TB-PET/CT indices ➡️ disease outcome measures in PsA
Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA
Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS
swethaann23 swethaann23 ( View Tweet)
Can we predict who which PsA pts will be radiographic progressors?
Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors
More data needed
#ACR21
@RheumNow
https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH
Robert B Chao, MD doctorRBC ( View Tweet)
New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro
Dr. Antoni Chan synovialjoints ( View Tweet)
Interesting study on immune cell profiling in PsA pts
⭐️variability in T cell sub-populations in PsA pts
⭐️no difference in lymphocyte cell populations before/after therapy
Abs#0056
https://t.co/16PYxaxT2S
#ACR21
@RheumNow https://t.co/dWaJr7hJ1p
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
▶️150 mg RZB vs Placebo
⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI
⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn
⭐️No safety signal
https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
Links:
Eric Dein ericdeinmd ( View Tweet)
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉phase 3 DBRPCT 24 weeks
👉150 mg week 0,4, 16 weeks
👉improved ACR20,ACR50,ACR70
👉improved PASI90
👉improved HAQ-DI
👉no increased safety signals
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
TheDaoIndex KDAO2011 ( View Tweet)
Promising results of Risankizumab for #psoriaticarthritis
🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo
🔸Well tolerated and showed no safety signals
@RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
sheila RHEUMarampa ( View Tweet)
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Olga Petryna DrPetryna ( View Tweet)
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
Dr. Rachel Tate uptoTate ( View Tweet)
New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Abst 0452 #ACR21 #acrbest @RheumNow TB-PET/CT in PsA helps differentiate from RA/OA &measure inflammatory burden. Main findings asymmetric synovitis,systemic enthesitis, DIP& extensor tendons inflammation& adjacent nail matrix inflammation, Sacroiliitis& diffuse spine enthesitis https://t.co/7nTSIbmKfE
Olga Petryna DrPetryna ( View Tweet)
#Fatigue is common in pts w/ #PsA- what is the impact on short-term disability?
Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs.
@RheumNow #ACR21 Abs#0239
https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1
Mrinalini Dey DrMiniDey ( View Tweet)
Excited for the first full day of #ACR21, reporting for @RheumNow!
Esp looking forward to:
⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes
⭐Plenary session
⭐Scientific sessions covering #axSpA, #PsA and more
Mrinalini Dey DrMiniDey ( View Tweet)
PsA bDMARD use in Australia🇦🇺
(where once you qualify for a bDMARD in general, it's the physician's free choice)
1. cool Sankey diagram showing switches
2. given the chance, people switch in all directions & switch hard
(registry linked with insurance)
#ACR21 ABST0201 @RheumNow https://t.co/jcVPa8jXsR
David Liew drdavidliew ( View Tweet)
